Pfizer Obtains Japanese Approval For Osteoporosis Drug Viviant
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare cleared Pfizer's once-daily Viviant (bazedoxifene) 20mg for market launch